Boehringer Ingelheim pays $650 mn to settle lawsuits

German pharmaceuticals maker Boehringer Ingelheim said Wednesday it has agreed to pay $650 million to settle around 4,000 lawsuits relating to its blood-thinning drug Pradaxa.

"Boehringer Ingelheim announced today that the has reached a comprehensive of state and federal cases in the US litigation regarding Pradaxa," it said in a statement.

Boehringer Ingelheim insisted that it continued to stand behind the drug, which is used to prevent and stroke by thinning the blood.

But Pradaxa has been blamed for more than 500 deaths caused by uncontrolled bleeding.

The German group insisted that the US Food and Drug Administration (FDA) has reaffirmed the "positive benefit-risk profile of Pradaxa."

"The settlement enables Boehringer Ingelheim to focus solely on its mission of improving patients' lives and allows the company to avoid the distraction and uncertainty of lengthy litigation. The settlement was closed at $650 million or approximately 470 million euros," the statement said.

The company said there were approximately 4,000 claims that it was seeking to resolve with this settlement.

"Boehringer Ingelheim expects most, if not all, of the plaintiffs to accept the terms of the settlement and Boehringer Ingelheim will vigorously defend against those who do not," the statement said.

"Notwithstanding our strong belief that we would prevail in these lawsuits, this settlement allows our company to avoid the distraction and uncertainty of protracted litigation over years and years," said the company's legal chief, Andreas Neumann.

add to favorites email to friend print save as pdf

Related Stories

French families file suit over alleged blood-thinner deaths

Oct 09, 2013

The families of four elderly people who died while taking an anti-clotting drug have filed a legal complaint against France's drugs safety body and Germany-based drugmaker Boehringer Ingelheim, their lawyers said Wednesday.

Lilly, Boehringer collaborate on diabetes drugs

Jan 11, 2011

(AP) -- Eli Lilly will pay Boehringer Ingelheim $387.4 million and collaborate with the German drugmaker to develop diabetes drugs with the U.S. pharmaceutical company facing the expiration of some of its key patents.

New blood thinner beats older drug for vein clots

Feb 20, 2013

(HealthDay)—People who need to take a blood thinner because they've had a clot in the deep veins of their legs appear to do better with the new drug Pradaxa (dibigatran) than with the older drug warfarin, ...

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments